Cycle modulation of insulin-like growth factor-binding protein 1 in human endometrium.

Endometrium is one of the fastest growing human tissues. Sex hormones, estrogen and progesterone, in interaction with several growth factors, control its growth and differentiation. Insulin-like growth factor 1 (IGF-1) interacts with cell surface receptors and also with specific soluble binding proteins. IGF-binding proteins (IGF-BP) have been shown to modulate IGF-1 action. Of six known isoforms, IGF-BP-1 has been characterized as a marker produced by endometrial stromal cells in the late secretory phase and in the decidua. In the current study, IGF-1-BP concentration and affinity in the proliferative and secretory phase of the menstrual cycle were measured. Endometrial samples were from patients of reproductive age with regular menstrual cycles and taking no steroid hormones. Cytosolic fractions were prepared and binding of (125)I-labeled IGF-1 performed. Cross-linking reaction products were analyzed by SDS-polyacrylamide gel electrophoresis (7.5%) followed by autoradiography. (125)I-IGF-1 affinity to cytosolic proteins was not statistically different between the proliferative and secretory endometrium. An approximately 35-kDa binding protein was identified when (125)I-IGF-1 was cross-linked to cytosol proteins. Secretory endometrium had significantly more IGF-1-BP when compared to proliferative endometrium. The specificity of the cross-linking process was evaluated by the addition of 100 nM unlabeled IGF-1 or insulin. Unlabeled IGF-1 totally abolished the radioactivity from the band, indicating specific binding. Insulin had no apparent effect on the intensity of the labeled band. These results suggest that IGF-BP could modulate the action of IGF-1 throughout the menstrual cycle. It would be interesting to study this binding protein in other pathologic conditions of the endometrium such as adenocarcinomas and hyperplasia.

[1]  B. Kahn,et al.  Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. , 1999, The New England journal of medicine.

[2]  E. Capp,et al.  Characterization of receptors for insulin-like growth factor type I on cultured human endometrial stromal cells: downregulation by progesterone. , 1996, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[3]  T. Rabe,et al.  Treatment of hyperandrogenism in women , 1996 .

[4]  L. Giudice,et al.  Growth factors and growth modulators in human uterine endometrium: their potential relevance to reproductive medicine. , 1994, Fertility and sterility.

[5]  L. Giudice,et al.  Insulin-like growth factor regulation of human endometrial stromal cell function: coordinate effects on insulin-like growth factor binding protein-1, cell proliferation and prolactin secretion , 1993, Regulatory Peptides.

[6]  H. Haring,et al.  Tyrosine kinase activity of insulin‐like growth factor I and insulin receptors in human endometrium during the menstrual cycle: Cyclic variation of insulin receptor expression , 1993, Fertility and sterility.

[7]  L. Giudice,et al.  Steroid and peptide regulation of insulin-like growth factor-binding proteins secreted by human endometrial stromal cells is dependent on stromal differentiation. , 1992, The Journal of clinical endocrinology and metabolism.

[8]  H. Häring,et al.  Insulin-like growth factor I-dependent tyrosine kinase activity in stromal cells of human endometrium in vitro. , 1992, The American journal of physiology.

[9]  R. Reynolds,et al.  Regulation of epidermal growth factor and insulin-like growth factor I receptors by estradiol and progesterone in normal and neoplastic endometrial cell cultures. , 1990, Gynecologic oncology.

[10]  E. Rutanen,et al.  Soluble 34K binding protein inhibits the binding of insulin-like growth factor I to its cell receptors in human secretory phase endometrium: evidence for autocrine/paracrine regulation of growth factor action. , 1988, The Journal of clinical endocrinology and metabolism.

[11]  M. Czech,et al.  Interaction of cross-linking agents with the insulin effector system of isolated fat cells. Covalent linkage of 125I-insulin to a plasma membrane receptor protein of 140,000 daltons. , 1979, The Journal of biological chemistry.